PPIs and In-Hospital Morbidity in Acute Variceal Bleeding with Chronic Liver Disease

Launched by UNIVERSIDAD AUTONOMA DE NUEVO LEON · Feb 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the use of a medication called Omeprazole may affect the health of patients with cirrhosis who experience variceal bleeding, which is a serious condition where large veins in the esophagus bleed due to increased pressure from liver disease. The goal is to understand if giving patients this medication during their hospital stay can help reduce complications such as confusion, infections, or re-bleeding.

To participate in the study, you must be an adult diagnosed with cirrhosis and experiencing variceal bleeding, without other serious conditions like shock or infections. If you are eligible and agree to join, you will be randomly assigned to receive either Omeprazole or not during your hospital stay. Researchers will track your recovery and any complications to see how the medication influences your hospital experience. It’s important to know that the study is taking place at a single hospital in Monterrey, Mexico, and they are currently looking for participants.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Adult
• • Cirrhosis
• • Variceal Bleeding with only endoscopic findings consistent with portal hypertension complications
• • Hypovolemic shock and Variceal bleeding
• Exclusion Criteria:
• • Shock of any type other than hypovolemic.
• • No cirrhotic patients
• • Patients that have Hepatic Encephalopathy at admission
• • Hepatorenal syndrome
• • Acute on chronic with CLIF-C \>50 points
• • Septic patients
• • Spontaneous Bacterial Peritonitis
• • Elimination Criteria
• • Voluntary removal of the study
• • Patients with confounding endoscopic findings (Erosive esophagitis, peptic ulcers, duodenal ulcers, GAVE, and atrophic gastritis).